Clinical Trials
32
6 active
Approvals
30
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
3
9.4%
Completed
23
71.9%
Not yet recruiting
3
9.4%
Recruiting
2
6.3%
Suspended
1
3.1%
- The North America prefilled syringes market is valued at USD 6.26 billion in 2025 and is projected to reach USD 17.46 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035. - Growth is driven by rising chronic disease prevalence, an aging population, increasing use of complex biologic drugs, and strong preference for self-administered injectable treatments at home. - Conventional prefilled syringes held a 62.00% share in 2025, while glass dominated the material segment at 78.00%, and diabetes led applications at 28.00%. - Key players including BD, Gerresheimer, SCHOTT Pharma, and West Pharmaceutical Services lead the market with specialized glass and polymer syringe systems.
- Terumo Corporation has launched VenoJect II RAPClot blood collection tubes in Japan, featuring Q-Sera's patented technology derived from snake venom proteins. - The innovative tubes reduce serum processing time to just five minutes, even from anticoagulated blood, representing the first major innovation in blood collection in decades. - Q-Sera is now seeking global partnerships to expand the RAPClot technology beyond Japan, potentially transforming laboratory diagnostics worldwide. - The technology uses recombinant ecarin proteins originally identified from snake venom to accelerate blood clotting and improve diagnostic accuracy.
- Terumo Interventional Systems received FDA 510(k) clearance for its OPUSWAVE Dual Sensor Imaging System, combining OFDI and IVUS technologies into a single catheter for coronary artery disease evaluation. - The DualView imaging catheter features a 150mm maximum pullback length, 2.6 Fr. imaging profile, and variable pullback speed up to 40mm/second in dual mode. - The system offers significant potential to reduce procedural time and costs while providing comprehensive imaging capabilities for interventional cardiologists performing image-guided PCI procedures. - This marks Terumo's imaging debut in the US market, building on their established leadership in single modality imaging in Japan.
- The Japanese Ministry of Health, Labour and Welfare approved national reimbursement for MedHub-AI's AutocathFFR System, effective October 1, 2025, following earlier regulatory approval by PMDA. - AutocathFFR represents the first fully automated, real-time AI-based fractional flow reserve solution that eliminates the need for pressure wires or hyperemic agents during coronary angiography. - The system applies advanced AI algorithms directly to routine angiographic images, producing physiology results instantly and reproducibly within procedures, addressing coronary artery disease assessment needs. - This milestone strengthens MedHub-AI's strategic collaboration with Terumo Corporation to accelerate adoption across hundreds of hospitals nationwide in Japan.
- OrganOx, the Oxford-based medtech company behind pioneering liver perfusion technology, has been acquired by Terumo Corporation for approximately $1.5 billion. - The company's metra device enables donor livers to be maintained in a functioning state outside the human body for up to 24 hours, transforming transplant outcomes. - The technology has been used in more than 6,000 liver transplants to date, significantly increasing the number of viable organs available for transplant. - The acquisition represents one of the largest exits of a UK medtech company and delivered BGF's biggest return to date with a 10x money multiple.
- MedHub-AI's AutocathFFR® becomes the first fully automated AI-powered software to receive PMDA approval in Japan for calculating Fractional Flow Reserve values directly from X-ray angiograms without invasive procedures. - The approval is supported by a pivotal study of 504 vessels demonstrating 93.7% diagnostic accuracy, 90.2% sensitivity, and 94.9% specificity compared to traditional invasive FFR measurements. - The company has partnered with Terumo Corporation for Japanese market distribution and expects FDA approval in the near future to accelerate global expansion. - AutocathFFR® delivers FFR results in just 37 seconds, eliminating the need for guidewires and vasodilatory drugs while providing operator-independent decision support for cardiologists.
- Terumo Neuro announced the commercial availability of the SOFIA Flow 88 neurovascular aspiration catheter in Europe, Middle East, and Africa markets, expanding their stroke treatment portfolio. - The new large-bore catheter features an 0.088-inch inner diameter with proprietary engineering enhancements designed for reliable trackability, proximal stability, and vessel-friendly flexibility. - The launch builds on the proven clinical performance of the SOFIA catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. - Clinical evidence from the SOFAST registry and SESAME trial evaluating the SOFIA Plus 6F as a first-line approach demonstrated strong results across speed, efficacy, safety and overall clinical outcomes.
- Terumo Neuro has received FDA Premarket Approval for its innovative Carotid Stent System, marking the first dual-layer micromesh carotid stent approved for use in the United States. - The device is indicated for treating carotid artery stenosis in high-risk patients, specifically those with ≥50% stenosis if symptomatic or ≥80% stenosis if asymptomatic, offering a new alternative to carotid endarterectomy. - The stent system accommodates vessel diameters between 3.5mm and 9.0mm at the target lesion, providing physicians with a clinically proven option to improve outcomes in carotid artery disease treatment.
